Filgrastim-laha (Filkri)
Optional dilutionFull monograph review pending
U.S. label preparation
Filkri · Optional dilution
- Preparation
- When IV dilution of the prefilled syringe is required, use 5% dextrose to reach 5 to 15 mcg/mL. Add human albumin to a final 2 mg/mL throughout this range. Saline can cause precipitation.
- Administration and handling
- Confirm the indication-specific infusion schedule and use the container materials listed in section 2.5.
Product and source details
Accord BioPharma Inc., · BLA761027
Product NDC: 69448-008, 69448-009
SPL effective 2026-07-10 | SPL version 3. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.